Safety of conventional immunosuppressive therapies for patients with dermatological conditions and coronavirus disease 2019: A review of current evidence. Issue 3 (28th December 2021)

• Record Type: Journal Article
• Authors: Arora, Harleen; Boothby‐Shoemaker, Wyatt; Braunberger, Taylor; Lim, Henry W.; Veenstra, Jesse
• Is Part Of: Journal of dermatology. Volume 49:Issue 3(2022)
• Page Start: 317
• Page End: 329
• Publication Date: 2021-12-28
• Subjects: autoimmune disease -- coronavirus disease 2019 -- dermatological agents -- dermatology -- Immunosuppression; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.16182
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: The effect of coronavirus disease 2019 (COVID‐19) on patients receiving conventional immunosuppressive (IS) therapy has yet to be fully determined; however, research on using IS therapy for treating COVID‐19 in acutely ill patients is increasing. While some believe that IS therapy may be protective, others argue that these agents may make patients more susceptible to COVID‐19 infection and morbidity and advocate for a more cautious, individualized approach to determining continuation, reduction, or discontinuation of therapy. In this review, we aim to provide an overview of COVID‐19 risk in dermatological patients who are receiving conventional IS therapies, including mycophenolate mofetil, methotrexate, cyclosporine, azathioprine, apremilast, JAK inhibitors, and systemic steroids. Additionally, we provide recommendations for management of these medications for dermatological patients during the COVID‐19 pandemic. Treatment of dermatological disease during the COVID‐19 pandemic should involve shared decision‐making between the patient and provider, with consideration of each patient's comorbidities and the severity of the patient's dermatological disease.